CXCL8 and neoplasm: Interestingly, CAR-T cells engineered to express the C-X-C motif chemokine receptor (CXCR) type 2, a receptor for IL-8, showed increased homing and anti-tumour efficacy in several solid tumour models in vivo, suggesting that IL-8 secretion can be exploited to achieve better treatments [142,146,147].